Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li, X Wang… - European journal of …, 2016 - Springer
Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
[HTML][HTML] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX …
Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
W Brückl, A Tufman, RM Huber - Expert Review of Anticancer …, 2017 - Taylor & Francis
Introduction: Based on the results of several randomised controlled trials, epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based …
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based …
Does EGFR mutation type influence patient-reported outcomes in patients with advanced EGFR mutation-positive non-small-cell lung cancer? Analysis of two large …
YL Wu, V Hirsh, LV Sequist, CP Hu, J Feng… - The Patient-Patient …, 2018 - Springer
Abstract Introduction In LUX-Lung 3 and LUX-Lung 6, afatinib significantly improved
progression-free survival (PFS) versus chemotherapy in patients with tumors harboring …
progression-free survival (PFS) versus chemotherapy in patients with tumors harboring …
Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress
J Bennouna, SR Moreno Vera - Future Oncology, 2016 - Taylor & Francis
In oncology, there is a clinical need for novel combination therapy regimens that maximize
efficacy and delay resistance to individual treatment modalities. Given the role of aberrant …
efficacy and delay resistance to individual treatment modalities. Given the role of aberrant …
Developments in pharmacotherapy for treating metastatic non-small cell lung cancer
A Rossi, PC Sacco, G Santabarbara… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Most patients with non-small cell lung (NSCLC), including squamous cell
carcinoma, adenocarcinoma and large cell carcinoma, have advanced disease at diagnosis …
carcinoma, adenocarcinoma and large cell carcinoma, have advanced disease at diagnosis …
An evolving algorithm to select and sequence therapies in EGFR mutation-positive NSCLC: a strategic approach
B Melosky, S Popat, DR Gandara - Clinical Lung Cancer, 2018 - Elsevier
The optimal treatment sequence for patients with metastatic epidermal growth factor receptor
(EGFR) mutation-positive (EGFR-M+) non–small-cell lung cancer (NSCLC) continues to …
(EGFR) mutation-positive (EGFR-M+) non–small-cell lung cancer (NSCLC) continues to …
Targeted therapy and precision medicine: More than just words in the treatment of lung cancer
DF Heigener, M Horn, M Reck - Der Internist, 2016 - Springer
Abstract Between 10 and 15% of non-small cell lung cancers (NSCLC) proliferate due to the
presence of a so-called driver mutation. This molecular alteration allows the cancer to …
presence of a so-called driver mutation. This molecular alteration allows the cancer to …
[PDF][PDF] Осимертиниб во второй линии терапии немелкоклеточного рака легкого с мутацией в гене EGFR
ДМ ПОНОМАРЕНКО, ДЮ Юкальчук… - Эффективная …, 2018 - umedp.ru
На конкретном примере проанализирован алгоритм лечения пациентки с
распространенным неплоскоклеточным немелкоклеточным раком легкого с мутацией в …
распространенным неплоскоклеточным немелкоклеточным раком легкого с мутацией в …
Advancing the Management of Non-small Cell Lung Cancer
DF Heigener - Journal-Advancing the Management of Non-small Cell … - touchoncology.com
Overview Advances in the development of targeted therapies and immunotherapy have
transformed the management of non small-cell lung cancer (NSCLC). Targeting …
transformed the management of non small-cell lung cancer (NSCLC). Targeting …